Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ: TARS )

42.38 -0.18 (-0.42%)
Streaming Delayed Price Updated: 9:38 AM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and... 
Via Benzinga
Tarsus Added to NASDAQ Biotechnology Index
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease
Via Benzinga
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Transition Plans for Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 211 companies set new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
Looking Into Tarsus Pharmaceuticals's Return On Capital Employed
According to Benzinga Pro data, during Q4, Tarsus Pharmaceuticals (NASDAQ:TARS) posted sales of $338.00 thousand. Earnings were up 5.39%, but Tarsus Pharmaceuticals still reported... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Rivian Automotive (NASDAQ:RIVN) was the largest... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 16.92% to $3.16 during Wednesday's regular session. The market value of their outstanding shares is at $87.... 
Via Benzinga
2 Biotech Stocks Wall Street Predicts Will Double
Biotechnology is advancing rapidly, driven by robust investments in new developments and a demand for synthetic biology. The industry is expected to continue to generate significant growth over an... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
Upgrades Keefe, Bruyette & Woods upgraded the previous rating for CBRE Group Inc (NYSE: 
Via Benzinga
3 Top Biotech Stocks to Buy Right Now
These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As of 12:33 EST, this security is trading at a volume... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Lydall, Inc. (NYSE: LDL) shares jumped 85.4% to close at $61.72 on Monday after the company agreed to be acquired by Unifrax for $61.10 per share. New Concept Energy,... 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Lydall Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 1.71% to 33,857.87 while the NASDAQ rose 0.63% to 14,119.16. The S&P also rose, gaining 1.28% to 4,219.92. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Anavex Life Sciences (NASDAQ:AVXL) shares moved upwards by 17.07% to $25.92 during Monday's regular session. Anavex Life Sciences's stock is trading at a... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 1.5%; Tarsus Pharmaceuticals Shares Slide
Midway through trading Monday, the Dow traded up 1.48% to 33,782.47 while the NASDAQ rose 0.74% to 14,134.01. The S&P also rose, gaining 1.17% to 4,215.39. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
31 Stocks Moving In Monday's Mid-Day Session
Gainers Lydall, Inc. (NYSE: LDL) shares climbed 82.3% to $60.68 after the company agreed to be acquired by Unifrax for $61.10 per share. Raven Industries, Inc. (NASDAQ: RAVN)... 
Via Benzinga
Tarsus Pharmaceuticals' TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) has reported topline data from Phase 2b/3 Saturn-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) in... 
Via Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.